CSL签署3.28亿美元研究合作，可选择Memo的免疫球蛋白抗体技术。
CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech
生命科学资讯
生物技术与制药领域的最新动态
人工智能如何重塑临床试验与市场准入
How AI Is reshaping clinical trials and market access
数据倍增效应：当专业知识、监控、系统与人工智能协同一致时
The Data Multiplier Effect: When Expertise, Monitoring, Systems, and AI Align
10x Genomics推出高通量单细胞检测，扩展Flex产品线 - MSN
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
10x Genomics (TXG) 是否正借力PharosAI与NHS的合作悄然重塑其空间生物学护城河？ - simplywall.st
Is 10x Genomics (TXG) Using PharosAI’s NHS Partnership To Quietly Recast Its Spatial Biology Moat? - simplywall.st
Illumina（ILMN）临床耗材激增是否悄然重塑其核心投资叙事？ - 雅虎财经英国
Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story? - Yahoo Finance UK
评估Illumina（ILMN）在近期股价疲软与长期回报波动后的估值 - simplywall.st
Assessing Illumina (ILMN) Valuation After Recent Share Price Weakness And Mixed Long Term Returns - simplywall.st
龙沙集团战略转型驱动强劲增长与股东回报——特别新闻
Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS
Hims因FDA反对取消销售复方GLP-1药丸计划
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
Hims因美国法律压力宣布停止销售GLP-1减肥药片。
Hims says it will stop selling GLP-1 pill, after legal pressure from US
#ACTRIMS26：赛诺菲公布托莱布替尼治疗原发性进展型多发性硬化症三期试验失败数据
#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS
重新审视赛默飞世尔科技（TMO）估值，近期股价疲软后的新视角 - simplywall.st
Taking A Fresh Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Weakness - simplywall.st
安捷伦的SLAS2026自动化推进可能改变投资安捷伦科技（A）的理由 - simplywall.st
Agilent’s SLAS2026 Automation Push Might Change The Case For Investing In Agilent Technologies (A) - simplywall.st
Hims与诺和诺德的对决；辉瑞月度GLP-1数据发布；第四季度财报汇总；及其他动态
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
龙沙集团发布部分信息不明公告，细节模糊引关注——TipRanks
Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks
Illumina (ILMN) 2025财年业绩后一次性收益塑造盈利叙事 - simplywall.st
Illumina (ILMN) One Off Gain Shapes Profitability Narrative After FY 2025 Earnings - simplywall.st
Illumina财报电话会议凸显临床增长势头 - TipRanks
Illumina Earnings Call Highlights Clinical Growth Momentum - TipRanks
美国呼吁司法部调查Hims公司涉及GLP-1药物问题
US calls for DOJ investigation of Hims over GLP-1 drugs
安捷伦科技公司（$A）CEO 2025年薪酬披露 - Quiver Quantitative
AGILENT TECHNOLOGIES, INC. ($A) CEO 2025 Pay Revealed - Quiver Quantitative
特朗普处方药计划启动遇冷，部分人指其普及性不足。
TrumpRx launch falls flat for some, citing generic access